|
Market Closed -
Nasdaq
04:00:00 26/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 788.04 USD | -1.00% |
|
+0.41% | +2.09% |
| 09-26 | US FDA approves Mirum's drug for rare bone disorder | RE |
| 09-24 | Regeneron Approaching Incremental Catalysts Like Upcoming Olatorepatide Data Readout, RBC Says | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- REGN Stock
- Consensus Regeneron Pharmaceuticals, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
